2002 Saab 9-3 Convertible No Reserve! on 2040-cars
Wayne, New Jersey, United States
Saab 9-3 for Sale
- 2006 saab 9-3 aero turbo 6speed manual leather sunroof alloys xenons pdc(US $5,980.00)
- 2009 saab 9-3 2.0t sport sedan front wheel drive clean carfax florida car(US $12,995.00)
- 2002 saab 9-3 se hatchback 4-door 2.0l(US $1,800.00)
- 2004 saab 9-3 arc 2.0l turbo convertible leather heat seats alloys xenons clean(US $5,980.00)
- 2008 saab 9-3 2.0t convertible 2-door 2.0l
- Saab 9-3 aero convertible(US $9,900.00)
Auto Services in New Jersey
Xclusive Auto Leasing ★★★★★
Willie`s Auto Body Works ★★★★★
United Motor Service ★★★★★
Ultrarev Inc ★★★★★
Turnersville Transmission Center ★★★★★
Troppoli Automotive Used Cars ★★★★★
Auto blog
GM wins appeal, dismissal of $3B Saab-related Spyker suit
Sun, Oct 26 2014It's been a long time since we last heard of the legal battles between Spyker CEO Victor Muller and General Motors, the automaker from which Muller's company purchased the embattled Saab brand back in 2010. To refresh your memories, after struggling through 2011 and entering into bankruptcy, Spyker attempted to save the Saab brand by selling it to a Chinese consortium. General Motors, though, blocked the sale because it did not want any of its intellectual property, of which Saab was in possession of from its days under the GM umbrella, in the hands of a potential rival automaker. Spyker then sued GM for intentionally blocking what it said was Saab's only chance of survival. The $3-billion suit was dismissed after a judge ruled in favor of GM, which apparently had granted a license to Saab to continue building cars using its technologies, but reserved the right to cancel that agreement if Saab again changed hands. Spyker appealed, and, according to Reuters, the appeals court upheld the previous ruling, again siding with GM. National Electric Vehicle Sweden, the company that eventually purchased Saab out of bankruptcy, managed to restart production for a short period before itself falling into financial trouble. We have at least another month to wait before hearing how Saab's next chapter may read.
Saab plant reopens, production to resume by year's end?
Mon, 19 Aug 2013Saab is gearing up to start production of the 9-3 again in September, two years after the last exampled rolled off the assembly line at the company's Trollhättan factory, Aftonbladet reports. Saab's new owner, National Electric Vehicle Sweden AB (NEVS), a Chinese-Japanese consortium created solely to buy Saab, says that the model's parts supply is the bottleneck in the production process, understandable since many of Saab's suppliers closed after it stopped production two years ago. The automaker also needs to establish a new dealership network. It is not entirely clear where Saab will market their new models, but North America is not expected to figure into their plans, at least initially.
Almost 400 factory employees are reportedly back working at Trollhättan, and Saab is looking to recruit 180 workers to help with production, presuming the factory can overcome its supply issues and go back online in the fall.
The new 9-3 is understood to be something short of an all-new car, a revision of the old 9-3 that started production in 2002. It will reportedly be offered initially as a four-door sedan and two-door convertible, and it will have a turbocharged engine, according to NEVS, which we expect will be a four cylinder. An electric 9-3 could come as early as next year. Turbocharged engines are part of Saab's DNA, NEVS Vice President Mattias Bergman has stated, and future Saab models will have them - despite the automaker's planned progression toward electric vehicles. The 9-3 will get small facelifts over time, says Mikael Östlund, a press officer at NEVS.
NEVS, the company that took over Saab, gets new majority owner
Wed, Jan 16 2019Chinese real estate conglomerate Evergrande Group, a key investor behind troubled electric vehicle startup Faraday Future, has acquired a 51 percent stake in NEVS. That's the Chinese-backed Swedish electric vehicle company that purchased the assets of Saab out of bankruptcy in 2012. The investment by subsidiary Evergrande Health Industry Group was valued at the equivalent of $930 million and is expected to help NEVS develop new EVs. Evergrande said it paid the first installment of $430 million on Jan. 15, with the remainder due by the end of the month. The remaining 49 percent stake is controlled by a holding company controlled by NEVS founder Kai Johan Jiang. "It means that NEVS will get a financial (sic) strong main owner who is very interested in developing our vision about green mobility transport solutions for the future," NEVS CEO Stefan Tilk said in a statement. NEVS, short for National Electric Vehicle Sweden, owns production facilities in Trollhattan, Sweden, and Tianjin, China, with another under construction in Shanghai. In late 2017 the company launched what apparently was limited production of the 9-3 EV, an electric vehicle based — you guessed it — on the old Saab 9-3 platform. The company now says it will be built in Tianjin starting later this year, with components coming from Trollhattan. It boasts a 186-mile range, in-car WiFi and a cabin air filter for the notoriously smoggy Chinese air. It also showed a battery-electric 9-3X concept at CES Asia in 2017, which is likely to be its next model pegged for production. The South China Morning Post, citing local media reports, says two of NEVS' models meet the standards for mass production in China. This content is hosted by a third party. To view it, please update your privacy preferences. Manage Settings. Definitely the best promotional video we've ever seen. Evergrande Health first came to Faraday Future's rescue back in 2017 with a promised $2 billion investment, but the two sides later went into arbitration in Hong Kong over a dispute about money following the first infusion of $800 million, leading the automaker to cut staff and wages last year, casting the future of FF into doubt. At the end of 2018, Faraday announced it had entered into a new restructuring agreement with an Evergrande Health subsidiary that sees them end litigation and jettison the previous investment agreement, taking Evergrande's investment in the company to 32 percent.